Clinical stage biotechnology company developing treatments against several food allergies.
EXIT in September 2015 : IPO on NASDAQ (DBVT).
Non-invasive medical diagnostic tools for Hepatology using Elastography.
EXIT in March 2011 : acquisition by Furui Group.
Drug development using red blood cells as drug delivery technology for cancer treatments. First product completed successfully its Phase III for the treatment of acute lymphoblastic leukemia. EXIT in November 2015 : IPO on Euronext Paris (ERYP).
New anti-cancer therapies using nanoparticles.